NCT06696417View on ClinicalTrials.gov

Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis

RecruitingOBSERVATIONAL
Enrollment

1,516

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Moderate to Severe Plaque Psoriasis
Interventions
DRUG

Drug group：vunakizumab (IL-17A inhibitor)

The recommended dose of vunakizumab was 240 mg, administered subcutaneously at weeks 0, 2, and 4, then every 4 weeks, with a final injection at 48 weeks

Trial Locations (1)

Unknown

RECRUITING

The First Hospital of China Medical University, Shenyang

All Listed Sponsors
lead

First Hospital of China Medical University

OTHER